TCM Biotech International Corp. (TPE:4169)

Market Cap	9.86B +195.6%
Revenue (ttm)	685.49M +2.8%
Net Income	19.17M -8.8%
EPS	0.32 -10.1%
Shares Out	59.05M
PE Ratio	514.40
Forward PE	n/a
Dividend	0.36 (0.22%)
Ex-Dividend Date	n/a

Volume	358,102
Average Volume	566,482
Open	175.50
Previous Close	176.00
Day's Range	166.50 - 175.50
52-Week Range	48.85 - 250.00
Beta	0.21
RSI	46.97
Earnings Date	Apr 17, 2026

About TCM Biotech International

TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for liver diseases. The company offers medical devices, such as therapy for osteoarthritis, intra-articular implant of hyaluronic acid, automated blood cell separator, absorbable adhesion barrier material, prosthetic and orthotic accessory, and pellefeel mask pressure relief pad; and pharmaceuticals, including iron supplement, therapeutic agent for urinary system, expectorant/mucolytic agent, anticancer drug, antihypertensive drug, and antidiabe...

• Industry: Pharmaceutical Preparations
• Founded: 1998
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 4169

Financial Performance

In 2025, TCM Biotech International's revenue was 685.49 million, an increase of 2.84% compared to the previous year's 666.53 million. Earnings were 19.17 million, a decrease of -8.76%.